

HOTEL & REGISTRATION INFORMATION

HOTEL VENUE

Participants requiring hotel accommodation should book directly with the hotels suggested below:

- **Sodehotel La Woluwe (avenue E. Mounier, 5 - 1200 Brussels)**
Phone +32 2 775 25 24 - Fax +32 2 770 47 80 - Email: reservation@sodehotel.eu
Single / Double: 155 Euros / 172 Euros (breakfast included)
- **Hotel Astrid (Place du Samedi, 11 - 1000 Brussels)**
Phone +32 2 219 31 19 - Fax +32 2 219 31 70 - Email: info@astridhotel.be
Single / Double: 107 Euros / 130 Euros (breakfast included)
- **Hotel Atlas (Rue du Vieux Marché aux Grains, 30 - 1000 Brussels)**
Phone +32 2 502 60 06 - Fax +32 2 502 69 35 - Email: sales@atlas.be
Single / Double: 105 Euros / 120 Euros (breakfast included)

A limited number of rooms have been reserved until 1st June 2009, after which rooms cannot be guaranteed. When you book your hotel room, please mention that it is for the "EORTC QOL PROBE EVENT 2009"

REGISTRATION

On-line registration is available at: <http://www.eortc.be/probe>

Deadline for registration (and payment for industry) is 2nd October 2009. As the number of places on this course is limited, participants are encouraged to register as soon as possible.

Registration fees & Payment	Course + Dinner for payment received BEFORE 1 st August 2009	Course + Dinner for payment received BETWEEN 1 st August & 1 st October 2009
Academics & non-profit organizations	Free	Free
Industry representatives	700 Euros	800 Euros

Participants are required to organise their own travel arrangements and pay for flights and accommodation.

Advanced registration and payment are required.

Registration (and corresponding payment for industry representatives) should be received before the indicated deadlines. Confirmation of your participation will be sent only upon receipt of complete registration data (and payment for industry representatives).

The language of the course is English.

CANCELLATION POLICY

Cancellation of registration has to be faxed or e-mailed to the EORTC Quality of Life Department.

For industry representatives: if under 2 months' notice of cancellation is given, 50% of the registration fee will be retained. If under 1 months' notice of cancellation is given, no refund will be paid. Refunds will be processed by bank transfer after the course.

For further information, please contact:

Ms. Irina GHISLAIN, EORTC Quality of Life Department
Avenue E. Mounier, 83, Bte 11 • 1200 Brussels, Belgium
Phone: +32 2 774 10 57 • Fax: +32 2 779 45 68
E-mail: irina.ghislain@eortc.be

INVITED FACULTY

Matti AAPRO, Clinique de Genolier, CH
Kristin BJORDAL, Norwegian Radium Hospital, NO
Andrew BOTTOMLEY, EORTC Headquarters, BE
Lily CLAASSENS, EORTC Headquarters, BE
Corneel COENS, EORTC Headquarters, BE
David COLLINGRIDGE, The Lancet Oncology, UK
Henning FLECHTNER, Klinikum Magdeburg, DE
Jan GEISSLER, European Cancer Patient Coalition (ECPC), UK
Carolyn GOTAY, University of British Columbia, CA
Eva GREIMEL, Medical University, Department of Gynecology, AUT
Madeleine KING, University of Sydney, AUS
Michael KOLLER, University of Regensburg, DE
John MARINGWA, EORTC Headquarters, BE
Francesca MARTINELLI, EORTC Headquarters, BE
Carol MOINPOUR, Fred Hutchinson Cancer Research Center, USA
Joana NAMORADO, European Commission, BE
David OSOBA, Quality of Life Consulting, CA
Mira PAVLOVIC, AFSSAPS representative, FR
Chantal QUINTEN, EORTC Headquarters, BE
Jolie RINGASH, The Princess Margaret Hospital, CA
Joseph SCHMUCKER - VON KOCH, University of Regensburg, DE
Jeff SLOAN, Mayo Clinic, USA
Martin TAPHOORN, Medisch Centrum Haaglanden-westende, NL
Yasuhiro TORIGOE, Pfizer, USA
Galina VELIKOVA, St. James's University Hospital, UK
Ulrich WEDDING, Universitaetsklinikum Jena, DE
Joachim WEIS, Clinic of Tumorbiology University of Freiburg, DE

CME Accreditation

The program of this event is submitted for CME accreditation to the ACOE (Accreditation Council for Oncology in Europe). We are seeking endorsement from the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS). Additionally, EORTC has applied for ESMO-MORA points Category 1 accreditation, permitting ESMO members a 25% reduction on registration fee.

Free Fellowship Offers

The Pfizer Foundation grant allows up to 20 fellowships which will be awarded to young academics (under 35 years old), advanced clinical students or those from developing countries for up to 600 Euros each. This will help to cover a part of the costs (e.g. travel, hotel, taxi fares, etc) to attend the symposium.

To apply send a two page CV with a letter of motivation (one page maximum) to the EORTC PROBE MANAGEMENT TEAM (probe@eortc.be). Deadline for applicants is July 15, 2009 and will be confirmed by August 15, 2009. The costs of attending (up to 600 Euros) will be refunded on receipt of the original invoices, following the meeting.

EORTC Course on

Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials

Free for Academics



25 - 27 November 2009

SODEHOTEL LA WOLUWE

Avenue E. Mounier, 5
1200 Brussels - Belgium

Chairman

Andrew Bottomley, PhD
EORTC Assistant Director
Head of EORTC Quality of Life Department

www.eortc.be/probe

PROBE

AIM OF THE COURSE

REGISTRATION FORM

This symposium aims to cover a broad range of topics in **HRQOL, Symptom Research and Cancer clinical trials**. It will address recent developments of EORTC tools, as well as other measures for use in clinical trials, but also have a broader focus including discussing international developments and research guidelines for the USA FDA, EMEA and HRQOL

in oncology. The faculty are international key opinion leaders in their field who will be able to provide a diverse view on HRQOL. Participants will learn aspects of designing, conducting and analyses of HRQOL in clinical trials.

Wednesday 25 November 2009

Academic and methodological issues Session Chairs: A. Bottomley & H. Flechtner

11.00 - 12.00 Registration & welcome coffee
12.00 - 12.05 Introduction (F. Meunier)
12.05 - 12.15 Welcome and aims of the symposium (A. Bottomley)
12.15 - 13.00 Introduction to HRQOL and EORTC tools (C. Quinten)
13.00 - 13.30 Basics of design and analysis of HRQOL protocol (C. Coens)
13.30 - 14.00 How to make a HRQOL measure the EORTC way (E. Greimel)

14.00 - 14.30 Coffee break

Methodology of trials with HRQOL issues Session Chairs: C. Quinten & M. King

14.30 - 15.15 Clinical significance in HRQOL area (M. King)
15.15 - 15.45 HRQOL in daily practice – Experience with EORTC tools (G. Velikova)
15.45 - 16.15 Using HRQOL as a prognostic factor - Fact or fiction (C. Quinten)
16.15 - 16.30 Coffee break
16.30 - 17.00 Does it make sense to assess HRQOL in brain cancer (M. Taphoorn)
17.00 - 17.30 How best to publish PRO and QOL studies in high impact factor oncology journals (D. Collingridge)
17.30 Summary and final remarks (C. Quinten)

Thursday 26 November 2009

Patients and regulatory views of HRQOL Session Chair: M. Aapro

09.00 - 09.15 Welcome and plan of the day (M. Aapro)
09.15 - 09.45 Why HRQOL is important to patients - A patient's perspective (J. Geissler)
09.45- 10.15 US and the FDA views on HRQOL (L. Claassens)
10.15 - 10.30 Coffee break
10.30 - 11.00 EMEA experience with HRQOL submissions (M. Pavlovic)
11.00 - 11.30 What do companies do with the FDA PRO guidance? (Y. Torigoe)
11.30 - 12.00 Ethical issues in EU research: enhancing successful applications for EU funding (J. Namorado)
12.00 - 13.00 Lunch

Thursday 26 November 2009 (Cont'd)

International Cooperative groups and HRQOL (lessons learned) Session Chair: D. Osoba

13.00 - 13.30 NCIC-CTG experience and success in cancer clinical trials (J. Ringash)
13.30 - 14.00 EORTC experience and success in cancer clinical trials (A. Bottomley)
14.00 - 14.30 Implementing interventions to enhance QOL in cooperative groups (C. Gotay)
14.30 - 14.45 Coffee break
14.45 - 15.15 Radiotherapy and HRQOL in international cancer clinical trials (K. Bjordal)
15.15 - 15.45 SWOG experience (C. Moynour)

Understanding optimal analysis of HRQOL data techniques for cancer clinical trials / Session Chairs: M. King & C. Moynour

16.00 - 16.30 Complex analysis strategies for longitudinal data (C. Coens)
16.30 - 17.00 Cluster analysis- can it add to your data? (F. Martinelli)
17.00 - 17.30 Fatigue: Can we measure it in cancer clinical trials? (J. Weis)
17.30 Summary and final remarks (C. Quinten)
20.00 GALA DINNER

Friday 27 November 2009

Debate - Session Chairs: H. Flechtner & C. Gotay

9.00 - 9.30 Genetics and HRQOL - Related or not - Pro (J. Sloan)
9.30 - 10.00 Genetics and HRQOL - Related or not - Con (H. Flechtner)

Translations and the future for HRQOL Session Chair: J. Sloan

10.00 - 10.30 Translations and HRQOL: What is the best approach? (M. Koller)
10.30 - 11.00 Ethical issues in randomized controlled trials (J. Schmucker - Von Koch)
11.00 - 11.30 New targeted therapies and what it means to HRQOL (C. Gotay)
11.30 - 12.00 Coffee break
12.00 - 12.30 Minimum Clinically Important Change in QOL based on Clinical Anchors (J. Maringwa)
12.30 - 13:00 Quality of Life in elderly patients (U. Wedding)
13:00 - 13:30 Quality of Life in childrens (H. Flechtner)
13.30 - 14.00 Looking back to go ahead (D. Osoba)
14.00 Goodbye address and symposium evaluation (A. Bottomley)

Title Prof Dr Ms Mrs Mr

Last Name _____ First Name _____

Institution / Company _____

Department _____

Address _____

Town _____ Country _____

Phone _____ PostCode _____ Fax _____

E-mail _____

Gender Female Male Age _____ Nationality _____

Speciality _____

ESMO Member Yes No ESMO Member ID Code _____

Industry representatives: the registration fee for the course is 700 € for payment received before 1st August 2009 (early rate) and 800 € for payment received between 1st August 2009 and 1st October 2009 (late rate). VAT is included. The deadline for payment is 2 October 2009.

Bank transfer: Fortis Banque SA, 14 av. de l'Astronomie, 1210 Brussels, Belgium
Account No. 210-0510010-36; IBAN BE46 2100 5100 1036; BIC/SWIFT GEBABEBB
Communication: "Registration Course QOL PROBE 2009 + Name of participant"

Signature _____ Date _____

Acknowledgments

We are grateful to the Pfizer Foundation for their financial support for this academic symposium, which has in part originated from a grant to the EORTC PROBE project.

